Key result
TGF-β signaling-interfering therapies represent a potential adjuvant approach for managing cardiac alterations in patients with Chagas disease.
Targeting the TGF-β pathway may serve as a novel adjuvant therapeutic strategy for managing cardiac complications in Chagas disease.
Answers are grounded in this paper and cite their sources.
TGF-β inhibition merits testing as Chagas cardiomyopathy adjunct; leaves open confirmation in randomized trials.
Transforming growth factor-β (TGF-β) influences the development of myocardiopathy in Chagas disease through regulation of (i) parasite invasion of heart cells, (ii) an intracellular parasite cycle, (iii) inflammation and immune response, (iv) heart fibrosis and remodeling, and (v) gap junction modulation and heart conduction. In this review, we discuss the rationale for developing TGF-β signaling-interfering therapies as adjuvant approaches for the management of the cardiac alterations of Chagas disease-affected patients.
No takes yet. Share an insight, caveat, or question.
Araújo-Jorge et al. (2012) conducted a review in Chagas disease. TGF-β signaling-interfering therapies was evaluated. TGF-β signaling-interfering therapies represent a potential adjuvant approach for managing cardiac alterations in patients with Chagas disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: